Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 22, 2022 - Issue 2
Submit an article Journal homepage
181
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia

Buendía Jefferson Antonioa Department of Surgery, Research Group in Pharmacology and Toxicology ”INFARTO”. Department of Pharmacology and Toxicology, University of Antioquia, Medellín, ColombiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2404-6612View further author information
ORCID Icon,
Diana Guerrero Patiñob Hospital Infantil Concejo De Medellín, Medellin, ColombiaView further author information
&
Melisa Lopez Morenob Hospital Infantil Concejo De Medellín, Medellin, ColombiaView further author information
Pages 299-305 | Received 25 Apr 2021, Accepted 16 Jun 2021, Published online: 28 Jun 2021

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Sajesh K. Veettil, Vanessa Vincent, Taylor Shufelt, Emma Behan, M. Sakil Syeed, Ammarin Thakkinstian, David C. Young & Nathorn Chaiyakunapruk. (2023) Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies. Journal of Asthma 60:9, pages 1702-1714.
Read now
Sara Alves, João Cavaleiro Rufo & José Crispim. (2023) Economic evaluation of biological treatments in patients with severe asthma: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 23:7, pages 733-747.
Read now
Jefferson Antonio Buendía, Carlos E. Rodriguez-Martinez & Monica P. Sossa-Briceño. (2023) Cost utility of vitamin D supplementation in adults with mild to moderate asthma. Journal of Asthma 60:5, pages 951-959.
Read now
Jefferson Antonio Buendía,Diana Guerrero Patiño. (2023) Fluticasone furoate plus vilanterol in patients with moderate persistent asthma: a cost-utility analysis. Journal of Asthma 60:2, pages 377-384.
Read now

Articles from other publishers (6)

S. V. Nedogoda, A. S. Salasyuk, S. N. Avdeev, I. N. Barykina, V. O. Lutova & E. A. Popova. (2023) Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 16:4, pages 527-536.
Crossref
Tomas Abbott, Carlos Balmaceda, Paula Zamorano, Andres Giglio & Manuel Espinoza. (2023) Cost-Effectiveness of Mepolizumab Add-On in the Treatment of Severe Eosinophilic Asthma in Chile. Value in Health Regional Issues 35, pages 69-77.
Crossref
Jefferson Antonio Buendía, Ricardo Hernández-Sarmiento & Jorge Enrique Rojas Medina. (2023) Cost-Utility of Continuous Positive Airway Pressure for Respiratory Distress in Preterm Infants in a Middle-Income Country. Value in Health Regional Issues 35, pages 1-7.
Crossref
Jefferson A. Buendía & Diana G. Patiño. (2022) Dupilumab in children with moderate‐to‐severe asthma: A cost utility analysis. Pediatric Pulmonology 57:10, pages 2313-2319.
Crossref
Jefferson Antonio Buendía & Diana Guerrero Patiño. (2021) Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma. BMC Pulmonary Medicine 21:1.
Crossref
Jefferson Antonio Buendía & Diana Guerrero Patiño. (2021) Cost-utility of as-needed ICS-formoterol versus to maintenance ICS in mild to moderate persistent asthma. BMC Pulmonary Medicine 21:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.